Sunshine Biopharma Inc. will cut its issued share count by 95 percent at the market open on Monday, October 26, 2026, when a one-for-twenty Sunshine Biopharma reverse stock split takes effect.

The Fort Lauderdale, Florida pharmaceutical company, which trades on Nasdaq under the ticker SBFM, announced the move on October 22, 2026. Issued and outstanding common stock falls from 15,219,383 shares to approximately 760,969 shares.

The company gave one reason: to regain compliance with Nasdaq’s minimum bid price requirement for continued listing. That rule sets the price floor a stock must hold to stay on the exchange.

The announcement does not state the share price before or after the split, the date Nasdaq notified the company of any deficiency, or whether a cure period or hearings process came first. Those details are absent from the source material.

What The Sunshine Biopharma Reverse Stock Split Actually Changes

Fifteen million two hundred nineteen thousand three hundred eighty-three divided by twenty is 760,969.15. The company’s stated figure of approximately 760,969 matches that arithmetic, which points to rounding rather than any new issuance of stock.

A reverse split reprices existing equity; it does not raise capital. The share count falls by the same factor the price per share rises, so market value is unchanged by the mechanics alone. What moves is the nominal price Nasdaq measures against its listing standard.

A TradingView summary of the announcement, produced by its automated analyst tool, calls the move a late-stage step to address ongoing bid-price noncompliance and notes that a smaller float can increase price volatility and widen trading spreads. It adds that the outcome depends on the post-split price holding.

That framing is consistent with the company’s own description. It is also a forecast, not a result. No post-split trading data exists yet, and none is contained in either document.

The Evidence Trail Is Short, And That Matters

Two documents describe this corporate action. One is the company’s press release, carried by Yahoo Finance and distributed through ACCESS Newswire. The other is the TradingView summary, which states plainly that it is based on the original press release from Sunshine Biopharma distributed by the same wire.

That means the share figures, the effective date and the compliance rationale trace back to a single disclosure. This report could not verify from the available material whether a separate U.S. Securities and Exchange Commission filing restates the same numbers. Until such a document is examined, the split details rest on the company’s own account.

The release also carries standard safe harbor language covering forward-looking statements about drug development activities, financial performance and future growth, with the company cautioning that actual results could differ materially. That caution applies to the growth claims made in the same release.

The Drug Portfolio Behind The Ticker

According to the announcement, Sunshine Biopharma has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled for launch in the remainder of 2026.

The company also describes a proprietary development program with two parts. K1.1 mRNA is an mRNA-lipid nanoparticle targeted at liver cancer. PLpro is a protease inhibitor, described as a small molecule for treating SARS Coronavirus infections.

The release gives no trial phase, enrollment figure, regulatory status or timeline for either program. That gap is significant: the two development candidates are the part of the business most likely to move the share price over time, and the disclosure offers no milestone a reader can date.

For a company whose near-term commercial activity sits in Canadian generics, the split leaves the portfolio, the launch schedule and the development programs untouched. It changes the ticker’s arithmetic only.

What Holders Outside The United States Should Note

For investors in Africa and other regions holding Nasdaq-listed microcaps, a split of this kind is a mechanical adjustment applied to the position and the quoted price at the open, not a change in the underlying security. Access to U.S. microcaps from most African markets runs through brokers offering American market execution.

This report could not verify how individual brokers in the region handle notification or any fractional residue from a one-for-twenty adjustment. Holders should confirm the treatment with their own custodian rather than assume a standard process. The company’s own contact for investor enquiries is its chief financial officer, Camille Sebaaly, listed in the release.

What To Watch After October 26

Three checkpoints sit ahead. The first is whether the post-split price holds above Nasdaq’s minimum bid threshold long enough to satisfy the exchange. The second is whether Nasdaq issues a written compliance determination; the release does not say how or when the company would announce one.

The third is operational. Roughly 12 generic launches are scheduled for the rest of 2026, and the company has flagged no timeline for K1.1 mRNA or the PLpro program. Any disclosure on either front would carry more weight than the share-count change.

Investors can also track the company’s own materials at sunshinebiopharma.com.

The Sunshine Biopharma reverse stock split settles a listing question. It does not settle a revenue question. Only the generic launch cadence and the development milestones can do that, and neither is dated in this announcement.

Follow AFRILATEST on Google News

Receive alerts for Sunshine Biopharma reverse stock split and more like it.

FIRST TIME REACTIONS:

Be the first to leave us a comment – Sunshine Biopharma Reverse Stock Split Set for October 26, down the comment section.

Advertisement

📌 Read more in our World News section.

JOIN US ON OUR SOCIAL MEDIA:

📘 Facebook | 🐦 Twitter | 📸 Instagram | 📌 Pinterest | ▶️ YouTube | 💼 LinkedIn | 🌀 Tumblr | 📖 Flipboard | 💬 WhatsApp | ✈️ Telegram

About Clare Dominic

Clare Dominic is the Editor at AfriLatest. With a background in journalism and a passion for storytelling, she oversees the editorial process to ensure content is accurate, engaging, and relevant. Clare works closely with contributors to maintain the highest standards of journalistic integrity across all news, sports, and lifestyle coverage.

View all articles by Clare Dominic

Walmart put a price on its challenge to Amazon and Costco this week: $120 a year. On Tuesday the retailer launched a Walmart membership bundle that folds Walmart+ and Sam’s Club Plus into a single subscription, according to Reuters. The timing is deliberate. The offer lands just before the holiday shopping season, in a year when Walmart’s own sales growth has slowed to its weakest pace in six years.

The mechanics are simple. Shoppers pay $120 annually for both tiers, a structure Business Insider reports means existing Sam’s Club Plus members effectively receive Walmart+ at no extra charge, while Walmart+ members can add the premium club membership for an additional $22.

What Is Confirmed Inside The Walmart Membership Bundle

Three elements are confirmed by the company: the $120 annual price, the pairing of the two Plus tiers, and the delivery promise attached to both. Walmart says Plus orders fulfilled from stores and clubs arrive in as little as 30 minutes, with some orders delivered in under 10 minutes.

That delivery speed is the actual product. Streaming entertainment, pharmacy services and partner deals are supporting perks, but the operational claim — that a store or club can function as a same-hour distribution node — is what Walmart is selling.

Walmart does not disclose membership counts or fee revenue. Every figure describing the size of these programs is an outside estimate, and should be labelled as such.

Furner’s Fee Comparison Is Framing, Not A Like-For-Like Price

CEO John Furner did not name competitors in his statement, but the reference was not subtle. “Consider what people may be paying today: $139 for a retail membership with delivery. $130 for a warehouse club,” he said. Business Insider identified those figures as the fees charged by Amazon and Costco respectively.

Two cautions apply. First, a fee comparison is not a value comparison; the $139 and $130 buy bundles of benefits that differ from Walmart’s. Second, the standalone Sam’s Club Plus fee is not stated in the published material, which makes the savings claim difficult to check independently. Reuters describes the bundle as offering a discount of nearly $100 versus buying the subscriptions separately, while Walmart’s own framing compares its $120 against rival fees of $139 and $130. Those are different arithmetic exercises, and readers should not treat them as interchangeable.

The one number that requires no estimate is the price: $120 for both.

Walmart Attacks From A Slowing Base

The context matters more than the press release. Reuters reports Walmart enters the holiday season amid weak consumer spending, particularly among lower- and middle-income households, and that Walmart, Target and Kroger have cut prices on thousands of items this year to attract budget-conscious shoppers.

Walmart reported its slowest quarterly comparable sales growth in six years in August, with average spend per visit also softening year over year. Costco and discount grocers such as Aldi have drawn stronger US traffic as shoppers hunt for convenience and value.

A separate Yahoo Finance report puts the second-quarter US same-store sales growth at 2.6%, the weakest since the fourth quarter of 2020, with grocery still the majority of US sales and private-label share up 1.3 percentage points year over year.

The scale gap is stark. Mizuho estimates roughly 25 million Walmart+ members and 30 million Sam’s Club members, with about 10% overlap between the two. Globally, Costco reported more than 150 million membership cardholders, and Amazon is estimated to hold more than 220 million Prime members. On those estimates, the $22 add-on targets a relatively narrow band of existing Walmart+ shoppers — which suggests the bundle is as much about retention and basket size as about recruiting new members.

Mizuho analyst David Bellinger framed it that way in a note: “The bundled offering screens as another signal of WMT pushing more value into its overall ecosystem, and highlighting its rapid delivery capabilities.”

Why African Retailers Should Watch The Fees, Not Copy The Model

The published reporting contains no detail on international availability. Both sources describe a US holiday season, US traffic patterns and US fee levels. No market outside the United States is named, and no non-US pricing is disclosed.

That absence is the relevant fact for readers in Africa and other regions. The 30-minute delivery claim depends on dense store and club networks plus last-mile capacity — infrastructure conditions that vary enormously by market. A $120 membership bundle built on that base is not a portable template; it is a US-specific play.

What travels is the pricing signal. Walmart, Target and Kroger cutting prices on thousands of items is evidence of a defensive posture in a soft spending environment. Suppliers and exporters who track US retail demand should read the bundle as a margin story rather than a growth story.

What To Watch Before The Holidays

Whether Walmart breaks its silence on membership counts. Whether Amazon or Costco adjust fees or bundle their own tiers in response. And whether the holiday quarter’s comparable sales figures show the bundle moving baskets or merely protecting existing ones. None of those outcomes is confirmed yet; all three are open questions.

The Big Picture

The Walmart membership bundle is best understood as a fee war dressed as a discount. Membership fees are recurring, high-margin revenue that funds delivery capacity, and Walmart is using its two-tier structure to compete on price against rivals whose combined scale it does not match. Furner’s statement sets the terms of that contest on Walmart’s chosen ground: the annual fee. Whether the $120 bundle changes shopping behaviour, or simply re-prices loyalty Walmart already had, will only become clear in the quarterly numbers that follow the holiday season.

Follow AFRILATEST on Google News

Receive alerts for Walmart membership bundle and more like it.

FIRST TIME REACTIONS:

Be the first to leave us a comment – Walmart Membership Bundle at $120 Takes Aim at Amazon, Costco, down the comment section.

Advertisement

📌 Read more in our World News section.

JOIN US ON OUR SOCIAL MEDIA:

📘 Facebook | 🐦 Twitter | 📸 Instagram | 📌 Pinterest | ▶️ YouTube | 💼 LinkedIn | 🌀 Tumblr | 📖 Flipboard | 💬 WhatsApp | ✈️ Telegram

Skechers and Kizik both claimed victory this week after judges at the Unified Patent Court in Munich ruled that a narrow set of Skechers step-in shoes infringes a patent owned by Kizik’s parent company, and ordered Skechers to stop making, distributing and selling those styles in 18 European countries.

The ruling was issued on Oct. 17 and confirmed through company statements over the following days. The Skechers Kizik patent dispute began in 2025, when Fast IP, LLC, the intellectual property holding company of HandsFree Labs, filed at the Munich court against Skechers’ Hands Free Slip-Ins range. The complaint also named Skechers’ German, Swiss, Belgian, Italian and French operations.

Hands-free footwear has become an increasingly important category for Skechers since the company introduced Slip-ins in December 2021. Skechers describes itself as the third-largest footwear company in the world. Kizik sells on the same premise: a shoe that goes on without hands.

What The Munich Court Actually Ordered

The panel did not hand Kizik everything it asked for. According to a copy of the decision reviewed by Footwear News, the injunction covers only sneakers built with a specific design combining elastic side panels and a heel stabilizer. Claims against certain other Skechers styles named in the original complaint were rejected.

The order binds Skechers across the 18 EU states participating in the court’s system: Belgium, Bulgaria, Denmark, Germany, Estonia, Finland, France, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Austria, Portugal, Romania, Slovenia and Sweden. Damages were also awarded. Either side can appeal.

When the case was filed in August 2025, the disputed amount carried a preliminary estimate of about 1 million euros, with 200,000 euros in provisional damages requested, according to FashionUnited. Set against Skechers’ $9.42 billion sale to 3G Capital, the money is minor. The injunction is the prize.

Why Both Sides Read The Skechers Kizik Patent Dispute As A Win

Both readings have support in the ruling, which is why the two statements do not contradict each other so much as describe different halves of the same document.

Gareth Hosford, chief executive of HandsFree Labs and Kizik, said the outcome “shows that the system works,” adding: “We’re pleased the court recognized the strength of our patent, and we’ll keep defending the technology our team built.

Skechers, in its own statement, counted the styles. “Skechers won on three of the four styles, with the fourth being a minor and commercially insignificant style for Skechers,” the company said in a release carried by Business Wire. It also quoted the court’s language that Kizik’s infringement claims were “largely unfounded.”

Both claims can hold at once. A finding of infringement on one commercially small style is still a finding of infringement, and it still carries a sales ban in the bloc. A rejection on three is still a rejection.

The Patent Counts Do Not Match

The two companies describe their patent portfolios in figures that have shifted over the life of the case. In July 2025, Skechers said it held more than 140 hands-free utility and design patents worldwide. By its October 2026 statement, that figure had become more than 300. HandsFree Labs, in the period when it filed, described holding more than 200 patents and applications worldwide.

Neither figure is independently verified in the material the companies released. The gap matters because Skechers has said it will “aggressively challenge both the validity of the patents and the infringement claims.” A validity fight turns on which specific claims survive review, not on portfolio totals cited in press releases.

What The Order Leaves Untouched

The injunction’s reach stops at the court’s participating states. Skechers says it sells in approximately 180 countries and territories through department and specialty stores, its website and more than 5,300 own retail stores. The banned styles can still be made and sold outside the 18-state bloc, subject to whatever other courts decide.

The complaint named Skechers’ Swiss arm, and Switzerland is not among the 18 states covered by the judgment. The enforcement map is drawn by treaty membership, not by where a company’s subsidiaries sit.

For buyers and distributors in Africa, Asia and Latin America, nothing in the Munich order changes the availability of the affected styles. What changes is European inventory. Kizik’s original complaint sought a recall of product placed on the market since July 9, 2025; the companies’ statements on the judgment do not specify how the court treated that request.

The American Case Is Still Open

The European action was a follow-on. HandsFree Labs filed a US suit on July 24, 2025, in the federal district court for the Eastern District of Texas, and that litigation remains ongoing. Skechers has argued its footwear uses its own technology and that Kizik’s patents are invalid.

Skechers president Michael Greenberg said in 2025 that the timing of the claims followed the 3G Capital deal: “We believe that, after all these years of silence, the true motivation for this lawsuit might be found right on the face of Kizik’s complaint, where they state that they are looking for a share of the $9.42 billion being paid for Skechers, money Kizik did not earn and does not deserve.”

That is an allegation by Skechers, not a court finding. No judgment has addressed motive, and Kizik has not conceded the point in any statement reviewed here.

What To Watch

Three markers will show whether the Skechers Kizik patent dispute changes the hands-free market or only its paperwork. First, whether Skechers appeals the Munich order and seeks a stay of the injunction while an appeal runs. Second, how the Texas case treats patent validity, since a European finding does not bind a US court. Third, whether the ruling pulls other step-in sellers into the Unified Patent Court’s reach. The court’s 18-state jurisdiction is now a tested venue for footwear patents, and both companies have said they intend to keep enforcing and challenging.

Follow AFRILATEST on Google News

Receive alerts for Skechers Kizik patent dispute and more like it.

Advertisement

FIRST TIME REACTIONS:

Be the first to leave us a comment – Skechers Kizik Patent Dispute: Both Sides Claim Victory, down the comment section.

📌 Read more in our World News section.

JOIN US ON OUR SOCIAL MEDIA:

📘 Facebook | 🐦 Twitter | 📸 Instagram | 📌 Pinterest | ▶️ YouTube | 💼 LinkedIn | 🌀 Tumblr | 📖 Flipboard | 💬 WhatsApp | ✈️ Telegram

About Clare Dominic

Clare Dominic is the Editor at AfriLatest. With a background in journalism and a passion for storytelling, she oversees the editorial process to ensure content is accurate, engaging, and relevant. Clare works closely with contributors to maintain the highest standards of journalistic integrity across all news, sports, and lifestyle coverage.

View all articles by Clare Dominic